

ASX and Media Release

Positive CAVATAK™ Combination Data Presented at 2014 Society for Immunotherapy of Cancer (SITC) Meeting

07 November 2014, Sydney, Australia: Viralytics Limited (ASX:VLA, OTC:VRACY) today announced the presentation of further results demonstrating improved CAVATAK™ anti-cancer activity when used in combination with immune checkpoint inhibitors at the 29th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland, USA.

The presentation included data from a preclinical study assessing the activity of CAVATAK given in combination with mouse homologues of either the anti-CTLA-4 monoclonal antibody, Ipilimumab or the anti-PD-1 monoclonal antibody, Pembrolizumab – two checkpoint inhibitors that represent a new, highly promising class of cancer immunotherapies. In both cases, the combination of CAVATAK with the checkpoint inhibitor produced superior efficacy outcomes in a mouse melanoma study, compared to the efficacy of either agent alone. CAVATAK is a proprietary formulation of a common cold virus that has been shown to preferentially infect and attack cancer cells.

The SITC meeting is the leading cancer immunotherapy conference with over 1,100 attendees, including scientists from academia, government and the pharmaceutical industry, along with other top medical professionals from around the world. Cancer immunotherapy treatments are forecast to become the single biggest class of therapeutics with the global market estimated at \$35 billion by 2023¹.

“We are pleased to present further positive data on CAVATAK at the premier global cancer immunotherapy conference,” Viralytics Chief Executive Officer Dr Malcolm McColl said, “We believe these updated results of CAVATAK used in combination with the checkpoint inhibitor agents represent a major opportunity for Viralytics to contribute to an exciting new field of cancer treatment.”

The poster focussing on the preclinical combination of CAVATAK and checkpoint inhibitors was presented by Viralytics Chief Scientific Officer, Dr Darren Shafren and is entitled:

Combination of a novel oncolytic immunotherapeutic agent, Coxsackievirus A21 and PD-1 or CTLA-4 blockade significantly reduces tumor growth in an immune competent mouse melanoma model

The poster presentation can be found on the Viralytics website at:

<http://www.viralytics.com/our-pipeline/scientific-presentations/scientific-presentations-2014/>

¹ <https://www.citivelocity.com/citigps/OpArticleDetail.action?recordId=209>

For personal use only



About Viralytics Ltd:

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics' lead investigational product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells. Together this mechanism of action is known as oncolytic immunotherapy. CAVATAK™'s preferential targeting of cancer cells creates the potential for a more tolerable cancer treatment.

The company has ongoing enrolment in a single arm Phase 2 clinical trial of intratumourally administered CAVATAK™ in the treatment of Late-stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US. The study is being conducted in patients with late stage (IIIC and IV) malignant melanoma.

In addition, Viralytics is progressing a Phase 1/2 trial of CAVATAK™ delivered systemically (intravenously). This trial, referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study, is enrolling patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. The STORM trial is being conducted at three UK cancer centres.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market.

Enquiries:

Dr Malcolm McColl
Chief Executive Officer
02 9988 4000

Mr Rudi Michelson
Monsoon Communications
03 9620 3333

For personal use only